Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 11;11(12):3364.
doi: 10.3390/jcm11123364.

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Enrico Zelin  1 , Carlo Alberto Maronese  2   3 , Arianna Dri  4   5 , Ludovica Toffoli  1 , Nicola Di Meo  1 , Gianluca Nazzaro  2 , Iris Zalaudek  1
Affiliations
Review

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Enrico Zelin et al. J Clin Med. .

Abstract

Background: Non-melanoma skin cancer (NMSC) stands as an umbrella term for common cutaneous malignancies, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together with rarer cutaneous cancers, such as Merkel cell carcinoma (MCC) and other forms of adnexal cancers. The majority of NMSCs can be successfully treated with surgery or radiotherapy, but advanced and metastatic stages may require systemic approaches such as immunotherapy with immune checkpoint inhibitors (ICIs).

Summary: Since immunotherapy is not effective in all patients and can potentially lead to severe adverse effects, an important clinical question is how to properly identify those who could be suitable candidates for this therapeutic choice. In this paper, we review the potential features and biomarkers used to predict the outcome of ICIs therapy for NMSCs. Moreover, we analyze the role of immunotherapy in special populations, such as the elderly, immunocompromised patients, organ transplant recipients, and subjects suffering from autoimmune conditions.

Key messages: Many clinical, serum, histopathological, and genetic features have been investigated as potential predictors of response in NMSCs treated with ICIs. Although this field of research is very promising, definitive, cost-effective, and reproducible biomarkers are still lacking and further efforts are needed to validate the suggested predictors in larger cohorts.

Keywords: Merkel cell carcinoma; basal cell carcinoma; biomarkers; cutaneous squamous cell carcinoma; immunotherapy; non-melanoma skin cancer; predictors.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

References

    1. Rogers H.W., Weinstock M.A., Feldman S.R., Coldiron B.M. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatol. 2015;151:1081. doi: 10.1001/jamadermatol.2015.1187. - DOI - PubMed
    1. Nehal K.S., Bichakjian C.K. Update on Keratinocyte Carcinomas. N. Engl. J. Med. 2018;379:363–374. doi: 10.1056/NEJMra1708701. - DOI - PubMed
    1. Lebbe C., Becker J.C., Grob J.-J., Malvehy J., del Marmol V., Pehamberger H., Peris K., Saiag P., Middleton M.R., Bastholt L., et al. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur. J. Cancer. 2015;51:2396–2403. doi: 10.1016/j.ejca.2015.06.131. - DOI - PubMed
    1. Becker J.C., Eigentler T., Frerich B., Gambichler T., Grabbe S., Höller U., Klumpp B., Loquai C., Krause-Bergmann A., Müller-Richter U., et al. S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin)–update 2018. JDDG J. Dtsch. Dermatol. Ges. 2019;17:562–576. doi: 10.1111/ddg.13841. - DOI - PubMed
    1. Bichakjian C.K., Olencki T., Aasi S.Z., Alam M., Andersen J.S., Blitzblau R., Bowen G.M., Contreras C.M., Daniels G.A., Decker R., et al. Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2018;16:742–774. doi: 10.6004/jnccn.2018.0055. - DOI - PMC - PubMed